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Heparanase (HPSE-1) is involved in the degradation
of both cell-surface and extracellular matrix (ECM)
heparan sulfate (HS) in normal and neoplastic tissues.
Degradation of heparan sulfate proteoglycans (HSPG)
in mammalian cells is dependent upon the enzymatic
activity of HPSE-1, an endo--D-glucuronidase, which
cleaves HS using a specific endoglycosidic hydrolysis
rather than an eliminase type of action. Elevated
HPSE-1 levels are associated with metastatic cancers,
directly implicating HPSE-1 in tumor progression. The
mechanism of HPSE-1 action to promote tumor progres-
sion may involve multiple substrates because HS is pres-
ent on both cell-surface and ECM proteoglycans. How-
ever, the specific targets of HPSE-1 action are not
known. Of particular interest is the relationship be-
tween HPSE-1 and HSPG, known for their involvement
in tumor progression. Syndecan-1, an HSPG, is ubiqui-
tously expressed at the cell surface, and its role in can-
cer progression may depend upon its degradation. Con-
versely, another HSPG, perlecan, is an important
component of basement membranes and ECM, which
can promote invasive behavior. Down-regulation of per-
lecan expression suppresses the invasive behavior of
neoplastic cells in vitro and inhibits tumor growth and
angiogenesis in vivo. In this work we demonstrate the
following. 1) HPSE-1 cleaves HS present on the cell sur-
face of metastatic melanoma cells. 2) HPSE-1 specifically
degrades HS chains of purified syndecan-1 or perlecan
HS. 3) Syndecan-1 does not directly inhibit HPSE-1 en-
zymatic activity. 4) The presence of exogenous synde-
can-1 inhibits HPSE-1-mediated invasive behavior of
melanoma cells by in vitro chemoinvasion assays. 5) In-
hibition of HPSE-1-induced invasion requires synde-
can-1 HS chains. These results demonstrate that cell-
surface syndecan-1 and ECM perlecan are degradative
targets of HPSE-1, and syndecan-1 regulates HPSE-1
biological activity. This suggest that expression of syn-
decan-1 on the melanoma cell surface and its degrada-
tion by HPSE-1 are important determinants in the
control of tumor cell invasion and metastasis.
Most of the molecular events associated with tumor growth,
neovascularization, and metastasis are influenced by interac-
tions between cancer cells and their extracellular matrix
(ECM)1 components. Heparan sulfate proteoglycans (HSPG),
along with other proteoglycans and structural proteins, are key
components of the cell surface and ECM (1–5). Heparan sulfate
(HS) polysaccharide chains in the ECM both bind and regulate
the activities of numerous signaling molecules (4, 6–12). Real-
ization that cell-surface HSPG mediate extracellular informa-
tion has raised questions about their selective degradation at
the HS chains level.
Heparanase (HPSE-1), is an endo--D-glucuronidase that
cleaves HS at specific intrachain sites, resulting in the forma-
tion of fragments of appreciable size (10–20 sugar units; see
Refs. 13–15). Of note, HPSE-1 is distinguishable from other
HS-degradative enzymes, such as heparitinases and hepari-
nases from Flavobacterium heparinum, or endoglucosamini-
dases, which are eliminases that cleave HS into di- or tetrasac-
charide units (16, 17). Increased levels of HPSE-1 activity are
associated with several tumor types (14, 18–20), including
brain metastatic melanoma (15, 21–23), and have been impli-
cated in tumor angiogenesis and metastasis (14). Tumor cells
transfected with HPSE-1 cDNA become more invasive and
acquire a highly metastatic phenotype (24). Our laboratory has
demonstrated that astrocytes produce HPSE-1 and could con-
tribute to the brain metastatic specificity of melanoma cells
(25). Furthermore, release of HS-bound paracrine growth fac-
tors affects the metastatic phenotype (26). Additionally,
HPSE-1 releases ECM-resident angiogenic factors in vitro, and
its overexpression induces an angiogenic response in vivo (14).
Syndecan-1, a transmembrane HSPG that binds both growth
factors and ECM components, acts as a co-receptor for multiple
growth factor receptors (2, 4–6, 27). Syndecan-1 expressed at
the cell surface is typically down-regulated in metastatic phe-
notypes. However, soluble syndecan-1 expressed in tumors has
been directly associated with increased invasion and cancer
progression (28–30).
Perlecan, the most abundant ECM HSPG of epithelial and
endothelial basement membranes, has been shown to promote
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invasive behavior (31). Down-regulation of perlecan expression
inhibits tumor growth and angiogenesis in vivo (32) and sup-
presses the invasive behavior of melanoma cells in vitro (33). A
recent study (27) has demonstrated that HS degradation un-
covers cryptic HS fragments that participate in controlling
tumor cell growth and metastasis. Enzymatic degradation of
HSPG HS chains by HPSE-1 is therefore likely to be involved
in fundamental biological processes ranging from normal de-
velopment to cancer metastasis. Although the precise mecha-
nisms by which they promote invasion are unknown, perlecan
and other cell-surface/ECM HSPG may enhance metastasis by
binding chemokines and growth factors which can then be
released by enzymatic degradation of HS.
Although several studies have reported HPSE-1 cloning (24,
34–36), molecular properties (13–14, 24, 34–36), expression
(25, 34–39), localization (34, 38), and involvement in cancer
progression (13–14, 23), heparanase targets have not been
thoroughly investigated. In the present study we have: 1) in-
vestigated HPSE-1 degradation of cell-surface HS in meta-
static melanoma cells; 2) determined whether purified synde-
can-1 and perlecan HS are degradative targets of HPSE-1; 3)
evaluated the relationship between syndecan-1 and the enzy-
matic activity of HPSE-1; and 4) assessed the modulation of
HPSE-1-induced invasion by syndecan-1 including the require-
ment for syndecan-1 HS chains.
EXPERIMENTAL PROCEDURES
Materials—Heparin, HS, and trypsin-EDTA were acquired from
Sigma. [35S]Sulfate (43 Ci/mg) was purchased from ICN (Irvine, CA).
DMEM, Ham’s F-12 nutrient medium were purchased from Invitrogen,
and FBS was from HyClone Laboratories (Logan, UT). WiDr cells were
obtained from the American Tissue Culture Collection (Manassas, VA);
guanidine hydrochloride was from Invitrogen, and CHAPS was from
Roche Applied Science. Heparitinase (F. heparinum, EC 4.2.2.8), chon-
droitinases AC (Arthrobacter aurescens; EC 4.2.2.5), and ABC (Proteus
vulgaris; EC 4.2.2.4) were from Seikagaku America, Inc. (Ijamsville,
MD). Transwell cell culture chambers were purchased from Corning
Glass, and MatrigelTM was obtained from Discovery Labware. All other
chemicals used were reagent-grade or better.
Tissue Culture—Early passage melanoma cells with high metastatic
abilities compared with parental cell lines of murine (B16B15b line; see
Refs. 21–23) and human origin (70W line; see Refs. 21–23), were main-
tained as monolayer cultures in a 1:1 (v/v) mixture of DMEM/F-12
supplemented with 5% FBS (B16B15b) or 10% (v/v) FBS (70W). Human
colorectal adenocarcinoma cells (WiDr) were maintained in RPMI sup-
plemented with 10% (v/v) FBS. Cells were maintained at 37 °C in a
humidified 5% CO2, 95% air (v/v) atmosphere and passaged using
EDTA (2 mM in PBS) or trypsin-EDTA (70W, WiDr) before reaching
confluence. WiDr cells were chosen as a source for perlecan because it
is the predominant cell-associated, high Mr proteoglycan they produce
(40–41).
Immunofluorescent Staining—Cells were plated at 10% density on
glass coverslips in DMEM/F-12, 5% (v/v) FBS, allowed to attach, and
grown for 24 h. Cells were then switched to DMEM/F-12, 5% FBS (v/v)
containing Hepes (10 mM, pH 6.3). Subsequently, recombinant HPSE-1
(200 ng/ml) was added to the appropriate wells, and cells were incu-
bated for 24 h at 37 °C. Cell-surface HS was detected with an anti-
heparan sulfate mAb 10E4 (1:50 dilution; Seikagaku America,
Falmouth, MA) followed by incubation with biotinylated anti-mouse
IgM (BioGenex Laboratories, San Ramon, CA) and rhodamine red-x-
streptavidin (1:400 dilution; Accurate Inc., Westbury, NY). Cells
stained for cell-surface syndecan-1 were plated as above and immuno-
stained with anti-syndecan-1 mAb 281.2 (1:100 dilution; see Ref. 30)
followed by a biotinylated goat anti-rat IgG (1:400 dilution, Santa Cruz
Biotechnology, Santa Cruz, CA) and rhodamine red-x-streptavidin
(Molecular Probes, Eugene, OR). Digital images were produced on an
axioplan fluorescent microscope (Carl Zeiss Microimaging Inc.,
Thornwood, NY) with advanced spot imaging program (Bio-Rad) using
identical conditions for all photographs and antibodies used.
Preparation of 35S-Labeled HS and Column Chromatography—WiDr
cells were used as a source of HS because the predominant HSPG
produced by WiDr cells is perlecan (40–41). WiDr cells were incubated
overnight (18 h) at 37 °C in a humidified 5% CO2, 95% air (v/v) atmo-
sphere in RPMI media lacking sulfate and supplemented with 33 mM
MgCl2, 15 mM Hepes, 1.2 gm/ml sodium bicarbonate, pH 7.3, containing
penicillin G (5 units), and penicillin-streptomycin sulfate (5 g). This
resulted in a final concentration of 10 M sulfate in the labeling media.
The labeling media contained 400 Ci/ml H2
35SO4 for a final specific
activity of 40 Ci/nmol. At the end of the labeling period, the media
were collected and precipitated with trichloroacetic acid-phosphotung-
stic acid as described previously (42). The material in the pellet was
subjected to incubation for 48 h at 37 °C in 0.1 M NaOH, 0.25 M sodium
borohydride (-elimination). At the end of the incubation, the solution
was neutralized with 1 N acetic acid and desalted over a Sephadex G-50
column (0.5  10 cm) eluted in PBS. The material eluting in the void
volume was pooled and defined as glycosaminoglycan. In both the
secreted and extracellular matrix fractions, 95% was HS as deter-
mined by sensitivity to nitrous acid degradation (42). This preparation
also was sensitive to bacterial heparitinases (17) but was resistant to
chondroitinases AC and ABC digestion (21). Specific activity was esti-
mated to be 2.6  108 dpm/g HS.
[35S]HS from WiDr cell-derived perlecan (1 pg) was incubated in the
presence or absence of HPSE-1 (200 ng) in 250 mM NaCl, 50 mM sodium
acetate, pH 5.0, for 24 h at 37 °C. Digestion of perlecan WiDr HS was
analyzed by liquid chromatography using a Sephacryl 300S HR column
(1.0  30 cm, Amersham Biosciences) (21). The resin was eluted with 4
M guanidine hydrochloride, 0.5% (w/v) CHAPS, 50 mM sodium acetate,
pH 6.0, at a flow rate of 0.4 ml/min; and fractions (0.4 ml) were collected.
Aliquots were then taken for determination of radioactivity by liquid
scintillation counting. Column void volume (Vo) and total volume (VT)
were assessed by the elution positions of blue dextran and vitamin B12.
Syndecan-1 Isolation and Removal of Core Protein or HS Chains—
Syndecan-1 was isolated from the culture media conditioned by CAG
myeloma cells transfected with a cDNA construct coding for the extra-
cellular domain of the human syndecan-1 core protein. Similar studies
using a cDNA coding for the extracellular domain of murine syndecan-1
have shown that it is secreted into the culture media as an intact
molecule bearing HS chains (30). For syndecan-1 isolation, culture
media were brought to a final concentration of 2 M urea and 50 mM
sodium acetate, pH 4.5, and incubated with DEAE-Sepharose fast flow
beads overnight (18 h) at 4 °C with gentle rocking. Beads were har-
vested by centrifugation and washed in PBS, and syndecan-1 was
eluted in PBS containing 1 M NaCl. Where indicated, syndecan-1 was
treated to digest either the core protein or HS before chemoinvasion
assays. To digest HS, syndecan-1 (250 ng) was incubated for 16 h at
37 °C with either HPSE-1 in 50 mM sodium acetate, pH 5.5, or with
heparitinase (1 mg/ml) in heparitinase buffer (10 mM Tris, pH 7.4, 150
mM NaCl, 4 mM CaCl2, 70 l final volume), and then the enzymes were
inactivated for 10 min at 50 °C (43). For experiments requiring free HS
chains, syndecan-1 (250 ng) was treated as above for -elimination (48
h at 37 °C in 0.1 M NaOH, 0.25 M sodium borohydride) to digest the core
protein. Alternatively, syndecan-1 core protein was digested with Pro-
nase (5 mg/ml; Sigma) for 16 h at 37 °C (44), and Pronase was then
inactivated for 15 min at 100 °C. Results shown are from multiple
experiments.
HPSE-1 Digestion of Syndecan-1 and Western Blotting—Purified
syndecan-1 (250 ng) was digested with active recombinant HPSE-1
(0–200 ng) in sodium acetate (80 mM), NaCl (250 mM) buffer, pH 4.5, for
24 h at 37 °C. Samples were then incubated for 10 min at 100 °C with
Laemmli sample buffer (45) and separated on a 4–20% Criterion gel
(Tris-HCl, Bio-Rad). Syndecan-1 was transferred to a zeta probe mem-
brane (Bio-Rad). The membrane was incubated in a blocking reagent
(3% (w/v) non-fat dry milk, 0.5% (w/v) bovine serum albumin in PBS, pH
7.5) for 1 h, and then 0.3% (w/v) Tween 20 buffer was added for an
additional 30 min. Syndecan-1 core protein was labeled using anti-
syndecan-1 mAb BB-4 (1:200 dilution; Accurate Chemical & Scientific
Corp., Westbury, NY) in blocking reagent, washed for 1 h with 6–8
changes of 0.5% Igepal (CA-630, Sigma) in Tris buffer (20 mM Tris, 150
mM NaCl, pH 7.4), and incubated with horseradish peroxidase anti-
mouse IgG (1:10,000 dilution; Accurate Chemical & Scientific Corp). It
then was washed and developed using the SuperSignal® West Femto
maximum sensitivity substrate (Pierce). Labeling was detected and
quantified using a Versadoc imaging system (Bio-Rad).
Chemoinvasion Assay—The invasive properties of melanoma cells
were assayed by use of invasive chambers followed by fluorescence plate
scanner analysis as described (21–23, 39). Briefly, cell invasion was
assayed by using Transwell cell culture chambers (8 m pore size, 6.5
mm diameter or 12 m pore size, 12 mm diameter) coated with Ma-
trigelTM (diluted 1:30 with cold DMEM/F-12, 100–300 l final coating
volume) that was applied to the upper filter surface and allowed to dry
before use. In assays where MatrigelTM was pretreated with HPSE-1,
MatrigelTM-coated filters were washed 3 times with DMEM/F-12 and
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then incubated with HPSE-1 (300 ng/ml, 100 l final volume in 10 mM
Hepes/DMEM/F-12, pH 6.8) for 16 h at 37 °C and then washed 10 times
with DMEM/F-12, pH 7.4, before adding cells for the indicated treat-
ments. For invasion assays, cells were added to the upper chambers
(4.0  104 cells/6.5 mm diameter chambers or 1.2  104 cells/12 mm
diameter chambers) with indicated amounts of purified HPSE-1 and/or
isolated syndecan-1. In some experiments, syndecan-1 (50 ng/ml), di-
gested to remove core protein/HS chains, or mock controls including
incubated enzyme/reagents and buffer were added with cells (300 l) to
the upper compartment of the chemoinvasion chambers (12 m pore) in
the presence of HPSE-1 (300 ng/ml). The lower chambers contained
N-formyl-L-methyl-L-leucine-L-phenylalanine (5 nM) in DMEM/F-12
with 10% (v/v) FBS as chemoattractant. Cells were incubated in inva-
sive chambers for 24–48 h at 37 °C in a humidified 5% CO2, 95% air
(v/v) atmosphere. Cells that invaded through the membrane were re-
leased from the lower side of the filter and the lower well by trypsin-
EDTA (10 min treatment; Sigma) after washing with 2 mM EDTA in
PBS, pH 7.4. They were then centrifuged and resuspended in cal-
cein-AM (2 g/ml; Molecular Probes, Eugene, OR) in Hanks’ balanced
salt solution. Cells with dye were incubated 40 min at 37 °C and read in
a 96-well plate using a Cytofluor 4000 multiwell fluorescent plate
reader (Applied Biosystems, Foster City, CA). Alternatively, to quantify
cell invasion, non-invasive cells were removed from the upper chambers
using cotton swabs, and invasive cells present on filters in lower cham-
bers were visualized using Diff-Quick Stain Kit (IMEB Inc., San
Marcos, CA) according to the manufacturer’s instructions, photo-
graphed with a Sony Digital Camera at fixed focus, using a Zeiss
Axiovert 25 microscope (Zeiss, Microimaging Inc., Thornwood, NY), and
counted.
HPSE-1 Assay—HPSE-1 activity was determined by degradation of
FITC-HS using high speed gel permeation column chromatography (see
Refs. 21–23; HPLC) as described previously (24, 39). Enzymatic activity
assays were performed at HPSE-1 optimal pH of 4.5 and at pH 6.8. 70W
melanoma cells rapidly acidify their medium, often to below pH 6.8
within 1 day in culture. Briefly, FITC-HS (6 g in 100 l total volume)
was incubated with purified and active recombinant HPSE-1 and with
or without purified syndecan-1 at indicated concentrations for 18–24 h
at 37 °C in 100 l of sodium acetate (50 mM, pH 4.5) or in reaction buffer
(heparin degrading kit adjusted to pH 6.8 with 1 M Tris-HCl;
Takara.Mirus.Bio). Reaction was terminated by adding heparin (100
g) and by heating samples for 5 min at 100 °C. Internal standards
(4-aminobenzoic acid (3 g/ml) and ovalbumin (3 g/ml) in 1 M Tris-HCl,
pH 8.0) were added to adjust pH and to provide quality controls for
HPLC. HS products yielded by heparanase reaction were analyzed by
size exclusion chromatography performed on an HP1090 liquid chro-
matograph with a photodiode array detector (Agilent Technologies Inc.,
Wilmington, DE) and an HP1046 programmable fluorescence detector
(Agilent Technologies Inc.). Samples were injected on a TSK-GEL
3000SWXL column (5 m, 7.8 mm  30 cm) with a TSK-GEL SWXL
guard column (5 m, 6.0 mm x 4.0 cm) from Tosoh Bioscience
(Montgomeryville, PA) at ambient temperature (25 °C). Samples were
isocratically eluted using Tris-HCl (25 mM), NaCl (150 mM), pH 7.5, at
a flow rate of 0.5 ml/min with a sample splitter placed between the
column and detectors to maintain a column pressure of less than 70 bar.
Fluorescence was monitored with excitation at 490 nm and emission at
520 nm, and then data were processed and peaks integrated using HP
ChemStation software (Agilent Technologies). HPSE-1 activity was de-
termined by measuring the decrease in fluorescence intensity in the
first one-half area of the intact FITC-HS peak chromatogram in com-
parison to no HPSE-1 (negative control).
Alternatively, a commercial HS degrading enzyme assay kit
(Takara.Mirus.Bio, Madison, WI) was used to determine purified
HPSE-1 activity, in the presence or absence of isolated syndecan-1.
Concentrations of syndecan-1 and HPSE-1 were incubated with bio-
tinylated-HS (b-HS) as indicated and detected by an ELISA-type assay
according to manufacturer’s instructions. Where indicated, buffer used
for HPSE-1 cleavage of bHS was adjusted to pH 6.0 (or pH 6.8) with 1
M Tris-HCl. Activity was determined by comparison to known amounts
of HPSE-1 present in this assay.
RESULTS
HPSE-1 Degrades Cell-surface HS in Melanoma Cells—To
determine the effect of HPSE-1 on cell-surface HS, HS expres-
sion before and after treatment of melanoma cells with purified
and active recombinant HPSE-1 was measured. HS expression
of murine brain metastatic melanoma cells (B16B15b) was
readily visualized using a monoclonal antibody to HS (Fig. 1, A
and C). Fig. 1 shows treatment of melanoma cells with HPSE-1
at both acidic (6.3) and physiologic pH (7.4). We chose to incu-
bate the cells at an acidic pH because tumors often generate an
acidic extracellular pH, and human HPSE-1 is more effective at
this pH (15, 24). B16B15b cells expressed high levels of cell-
surface HS at both pH conditions. Treatment with HPSE-1 (24
h at 37 °C, pH 6.3) resulted in a significant reduction of the
cell-surface HS (Fig. 1B). HPSE-1 activity at pH 7.4 was suffi-
ciently low that we were unable to detect a significant reduc-
tion in HS expression by immunofluorescence analysis (Fig.
1D). This confirms previous reports of lower HPSE-1 activity at
physiologic (pH 7.4) versus acidic pH (26, 47). A more extensive
digestion of HS may be needed to detect changes in HS expres-
sion through immunofluorescence than would be required for
HPSE-1-induced activity in biological determinations such as
invasion assays.
Of relevance, syndecan-1 is a cell-surface HSPG expressed
on B16B15b cells (Fig. 1E; data not shown). Syndecan-1 is lost
from the cell surface under a number of physiological condi-
tions (5). Furthermore, degradation of HS can result in changes
in syndecan-1 distribution (5, 47). To determine whether re-
moval of HS resulted in a loss of cell-surface syndecan-1 core
protein, B16B15b cells were treated with HPSE-1, and synde-
can-1 expression was detected using a specific monoclonal an-
tibody to its core protein. Syndecan-1 core protein was still
expressed on the cell surface of HPSE-1-treated cells at levels
undistinguishable from non HPSE-1-exposed cells (Fig. 1, E
and F). However, under the same conditions there was a sig-
nificant reduction in cell-surface HS (Fig. 1, A and B).
HPSE-1 Degrades Syndecan-1 and WiDr Perlecan HS—
HPSE-1 is known to not only promote cell invasion but also to
induce angiogenesis by modulating growth factor activity and
bioavailability (14, 39). However, little is known of its direct
action on specific HSPG targets and their modulation/interac-
FIG. 1. Cell-surface HS is degraded by HPSE-1, but syndecan-1
core protein is not removed by HPSE-1 treatment. Melanoma
(brain metastatic B16B15b) cells were plated on glass coverslips in
DMEM/F-12 with 10% FBS and incubated for 24 h at 37 °C, 5% CO2.
The medium was then removed and replaced with DMEM/F-12 at pH
6.3 (A and B) or pH 7.4 (C and D) in the absence (A, C, and E) or
presence (B, D, and F) of purified recombinant HPSE-1 (200 ng/ml).
Subsequently, cells were surface-labeled with anti-HS mAb (A–D) fol-
lowed by biotinylated anti-mouse IgM and rhodamine red-x-streptavi-
din. Additionally, cells were surface-labeled with anti-syndecan-1 mAb
(281.2) (E and F) followed by biotinylated anti-rat immunoglobin and
rhodamine red-x-streptavidin. Digital images were produced on an
Axioplan fluorescent microscope (Carl Zeiss Inc., Thornwood, NY) with
an advanced spot imaging program using identical conditions for all
photographs and antibodies used.
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tions during HPSE-1-driven invasive events. To determine pre-
cisely which HSPG are digested by HPSE-1, we incubated
purified preparations of syndecan-1 and perlecan HS with pu-
rified active recombinant HPSE-1. Syndecan-1 was digested
with increasing concentrations of HPSE-1, and its core protein
was detected by Western blot analysis. Syndecan-1 was de-
tected as a broad band at 220 kDa (Fig. 2). The broad band
and large molecular weight are due to the presence of HS
chains and aggregation of the syndecan-1 core protein as re-
ported previously (48, 49). HPSE-1 exposure (50 ng for 24 h at
37 °C) of syndecan-1 resulted in a discrete degradation of its
HS giving two different sized bands (Fig. 2). These bands were
still aberrantly large indicating that HS chains and protein
core aggregation still influenced protein mobility. Further-
more, HPSE-1 characteristically digests HS chains at discrete
interior sites rather than acting by a progressive removal of
sugar subunits from the chains (13–15, 50). Because the num-
ber of cleavage sites/HS chain is also finite, studying HPSE-1
enzymatic activity requires extended incubations to detect deg-
radation of HS chains by chromatographic methods (24, 35, 46,
51). Digestion with increasing amounts of HPSE-1 (200 ng)
using the same conditions resulted in further digestion of syn-
decan-1 to an 120-kDa band (Fig. 2A). Studies have shown
that small quantities of chondroitin sulfate chains and incom-
pletely digested HS fragments attach to syndecan-1 core pro-
tein and prevent the formation of a tight band (52).
We digested WiDr HS preparations with purified HPSE-1.
WiDr cells secrete primarily one type of HSPG as large intact
proteoglycan (41) previously identified as perlecan (40). Perle-
can is also the major HSPG present in the basal lamina and in
MatrigelTM, a commercial basement membrane used as coating
ECM barrier in in vitro chemoinvasion assays. 35Sulfate-la-
beled HS from WiDr cells-derived perlecan was exposed to
HPSE-1, and radiolabeled HS digestion products were sepa-
rated by Sephacryl 300S HR column chromatography. Undi-
gested perlecan HS eluted significantly before HPSE-1-di-
gested perlecan HS products (Fig. 3), demonstrating that
HPSE-1 degraded perlecan-derived HS into smaller fragments.
Similar results were obtained using HS from WiDr cell-
secreted ECM (data not shown).
Syndecan-1 Inhibits HPSE-1 Stimulation of Melanoma Cell
Invasion—The effects of syndecan-1 and HPSE-1 on the inva-
sive capacity of melanoma cells were determined by seeding
cells (highly brain metastatic 70W) onto MatrigelTM-coated
filters in Transwell units. In this assay, cells in the top well
unit adhere to and penetrate the coated filters and then enter
the lower chamber (22). Melanoma cells incubated with synde-
can-1 and/or HPSE-1 were added to the upper chambers and
allowed to invade for 48 h before analysis. HPSE-1 added with
cells stimulated invasion through the MatrigelTM barrier 8-fold
over untreated cells (Fig. 4). Importantly, co-incubation of ex-
ogenously added syndecan-1 with HPSE-1 inhibited hepara-
nase-induced invasion. Presence of syndecan-1 alone in the
upper chambers did not affect the basal invasion of cells. These
data indicate that addition of soluble syndecan-1 ectodomain
can act to inhibit HPSE-1-specific stimulation of melanoma cell
invasion in vitro (Fig. 4).
The inhibition of HPSE-1-stimulated invasion is dependent
upon the concentration of syndecan-1 present. First, an
HPSE-1 concentration (100 ng/ml) was used to stimulate max-
imal penetration of 70W cells through the invasion chambers.
Second, by using syndecan-1 at a similar concentration (100
ng/ml), inhibition of invasion was observed (p  0.001 com-
pared with HPSE-1 exposure (100 ng/ml); Table I). Syndecan-1
also inhibited HPSE-1-induced invasion when a 10-fold lower
syndecan-1 concentration (10 ng/ml; p  0.001 compared with
HPSE-1 (100 ng/ml)) was present in these assays. This is a
significantly lower molar amount of syndecan-1 (10 ng/ml or
0.23 nM) than HPSE-1 (100 ng/ml or 1.7 nM). Lower concentra-
tions of syndecan-1 (1 ng/ml or 23 pM) were unable to inhibit
HPSE-1-stimulated invasion.
HPSE-1 could be degrading both the matrix and syndecan-1
during the invasion assay. We therefore pretreated the Ma-
trigelTM coating the invasion chamber with HPSE-1 (300 ng/
ml) to digest HS in the matrix, and then extensively washed
the MatrigelTM prior to adding cells and syndecan-1. HPSE-1
digestion of the matrix prior to the initiation of the invasion
assay increased the number of invading cells (Table II). Syn-
FIG. 2. Purified syndecan-1 is degraded by HPSE-1. A, synde-
can-1 (250 ng/assay) was degraded with increasing concentrations of
HPSE-1 (0, 50, or 200 ng/assay) for 24 h at 37 °C in 20 mM sodium
acetate, pH 4.5, and 250 mM NaCl. Syndecan-1 was analyzed by West-
ern blotting analysis with an anti-syndecan-1 core protein antibody
(BB-4) and HRP-anti-mouse IgG mAb followed by using the SuperSig-
nal West Femto maximum sensitivity substrate. Bands were visualized
on a Versadoc imaging system. Results shown were consistently ob-
tained in four independent experiments. B, quantification of size
change was determined by analyzing the Western blotting for optical
density of syndecan-1 staining versus RF values using Quantity One
quantitation software for treatment with 0 (O), 50 (E), and 200 ng (f)
of HPSE-1.
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decan-1 added with the cells at the beginning of the invasion
assay inhibited the increased invasion through HPSE-1-pre-
treated matrix.
Syndecan-1 is composed of a core protein and HS chains
which may act independently or in concert to inhibit HPSE-1-
induced melanoma cell invasion. To examine these possibili-
ties, we first degraded either the core protein or the HS chains
prior to their addition to the invasion assays. Second, enzymes
were inactivated prior to their addition to the invasion assay
and did not interfere with it (Table III). Heparitinase leaves the
core protein intact but cleaves the HS chains into di- and
tetrasaccharides that are too small to facilitate biological ac-
tivity, such as growth factor binding. Syndecan-1 core protein
from heparitinase-treated syndecan-1 was unable to inhibit the
HPSE-1-induced melanoma cell invasion (Table III). However,
syndecan-1 pretreated with HPSE-1 was still capable of inhib-
iting the HPSE-1-induced invasion. HPSE-1 cleaves HS chains
into relatively large fragments that could retain biological ac-
tivity. HPSE-1 may also leave sufficient HS attached to the
core protein to allow binding of growth factors or ECM compo-
nents to partially denuded core protein. As an alternative ap-
proach, we digested syndecan-1 core protein by using the
-elimination procedure or by Pronase incubation, both of
which leave the HS chains intact. Free HS chains from synde-
can-1 inhibited the HPSE-1-induced invasion. Together, these
data indicate that HS chains are required for syndecan-1 to
inhibit HPSE-1-induced invasion and that syndecan-1 HS
chains digested with HPSE-1 still retain their active sites.
To evaluate if other HSPG would also inhibit HPSE-1-stim-
ulated invasion, WiDr perlecan HS was added with melanoma
cells in invasion assays. Unlike syndecan-1 HS, WiDr perlecan
HS did not inhibit HPSE-1-stimulated invasion nor change the
basal invasive values of these cells (Fig. 5).
Syndecan-1 Does Not Directly Inhibit HPSE-1 Activity—
Mechanisms by which syndecan-1 inhibits invasion in mela-
noma cells are presently not known (5). We have shown that
syndecan-1 can inhibit invasion through HPSE-1-pretreated
MatrigelTM where soluble HPSE-1 has been removed prior to
the start of the invasion assay (Table II), indicating that syn-
decan-1 does not directly inhibit HPSE-1 activity. However,
syndecan-1 could be acting on HPSE-1 bound to the matrix
which cannot easily be removed by washing. Therefore, to
directly assess if syndecan-1 acted as an inhibitor of HPSE-1
enzymatic activity, we measured heparanase activity in the
presence of syndecan-1 using several sources and derivatives of
HS, FITC-labeled HS and biotinylated HS. The first assay
consisted of preparing FITC-HS and analyzing HPSE-1 degra-
dation by HPLC analysis (Refs. 24 and 39; see also “Experi-
mental Procedures”). FITC-HS was incubated alone (negative
control), with HPSE-1 (positive control), syndecan-1, or with
FIG. 3. WiDr HS is degraded by HPSE-1 and WiDr HS degra-
dation is not inhibited by syndecan-1. [35SO4]HS from WiDr cells
was treated in the presence (f) or absence () of HPSE-1 (200 ng/assay
for 24 h at 37 °C, pH 4.5). The products were then separated by
Sephacryl 300S HR chromatography in 4 M guanidine-HCl, 0.1% (w/v)
CHAPS, in 50 mM sodium acetate (pH 6.0; 0.4 ml fractions). Elution of
the [35SO4]HS was detected by liquid scintillation counting. Column Vo
and VT values are indicated by arrows.
FIG. 4. Syndecan-1 inhibits HPSE-1-stimulated invasion of
melanoma cells. Brain metastatic melanoma cells (70W) were placed
in invasion chambers (8 m pores) in the presence or absence of HPSE-1
(100 ng/ml or 1.7 nM), syndecan-1 (200 ng/ml or 2.3 nM), or both, and
incubated in DMEM/F-12 for 24 h at 37 °C. At that time, the medium in
the upper chambers was exchanged for fresh DMEM/F-12, and invasion
assays were continued for additional 24 h. A trypsinization step was
then applied releasing invasive cells from lower wells and Transwell
filters (see ‘‘Experimental Procedures’’). Cells were subsequently la-
beled with calcein-AM for 30 min at 37 °C and detected using a Cyt-
ofluor fluorescence plate reader. Cell numbers were calculated from a
standard curve of known number of cells and increased invasions (fold)
are reported. Bars represents the mean  S.D. of triplicate determina-
tions (*, p  0.001). Student’s t test was used as statistical method.
TABLE I






0 0 13  2
100 0 54  1a
100 0.001 62  16a
100 0.01 47  7a
100 0.1 59  9a
100 1 42  6a
100 10 13  3b
100 100 17  6b
a p  0.005 when compared with negative control (no HPSE-1 and no
syndecan-1).
b p  0.001 when compared with positive control (HPSE-1 (100 ng/ml)
with no syndecan-1). Student’s t test was used as statistical method.
TABLE II
Syndecan-1 inhibition of melanoma invasion through






0 0 38  4.0
300 0 78  2.3a
0 100 42  1.1
300 100 18  2.1
a p  0.005 when compared with negative control (no HPSE-1 pre-
treatment and no syndecan-1 treatment). Student’s t test was used as
statistical method.
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both syndecan-1 and HPSE-1. Syndecan-1 and HPSE-1 concen-
trations in this assay were in the same range as the ones used in
invasion assays. HPSE-1 concentration was chosen to readily
detect any inhibition of activity (Fig. 6C) with heparanase activ-
ity subsequently analyzed by HPLC. By using this approach,
FITC-HS degraded by HPSE-1 had a longer retention time than
the control, undegraded FITC-HS (Fig. 6) (24, 39). When syn-
decan-1 was co-incubated in HPSE-1 activity assays, FITC-HS
was specifically degraded, indicating that HPSE-1 was still ac-
tive in the presence of syndecan-1. Similar results were obtained
when syndecan-1 was predigested by HPSE-1 and then added to
the reaction mixture (data not shown).
To further investigate any changes in HPSE-1 activity in
response to syndecan-1, we used an ELISA at concentrations
where we could detect a 2-fold decrease in HPSE-1 enzymatic
activity at very low HPSE-1 concentrations. In this assay,
HPSE-1 degrades a b-HS fragment. Undegraded b-HS is bound
to a bFGF ELISA plate, and its degradation is detected by
HRP-streptavidin. The b-HS fragment is specifically designed
so that when it is degraded it is not bound and results in a
lower HRP signal. By this methodology, we were able to dis-
tinctly measure HPSE-1 activity and detect a 50% decrease of
its enzymatic activity at pH 6.0 (Fig. 7B). Accordingly, HPSE-1
concentration in this assay was lower than the one used in the
invasion assay. Importantly, syndecan-1 did not inhibit
HPSE-1 activity even at concentrations at much higher ratios
than HPSE-1 concentrations used in invasion assays (Fig. 7).
We also performed this assay at pH 7.4 resulting in negligible
HPSE-1 activity. Again, this confirms previous reports (26, 47)
of lower HPSE-1 activity at physiologic (pH 7.4) versus acidic
pH. Furthermore, because 70W melanoma cells used in this
assay rapidly acidify the culture medium, we have performed
experiments using intermediate pH conditions (pH 6.8). As
expected, HPSE-1 was less active at pH 6.8 (Fig. 8B) than at
pH 7.4 (Fig. 8C). Although the overall level of FITC-HS degra-
dation was lower at pH 6.8, HPSE-1 had the same level of
enzymatic activity in the presence (0.2  0.1 fraction HS di-
gestion) or absence of syndecan-1 (0.2  0.1 fraction HS diges-
tion; Fig. 8A). Combined, these data demonstrate that HPSE-1
enzymatic activity is not being directly inhibited by syndecan-1
in invasion assays.
DISCUSSION
In this report we demonstrate for the first time that HS from
purified syndecan-1 and perlecan are degradative targets of
heparanase (HPSE-1). Furthermore, this work provides the
first evidence: 1) that HPSE-1 cleaves HS present on the cell
surface of metastatic melanoma cells; 2) that HPSE-1 cleaves
HS of purified syndecan-1 and HS chains isolated from the
medium and matrix of WiDr cells, which primarily secrete
perlecan; 3) that syndecan-1 does not inhibit HPSE-1 digestion
of HS; and 4) that syndecan-1 inhibits the HPSE-1-mediated
invasive effects of melanoma cells by in vitro chemoinvasion
assays. This inhibition is dependent upon syndecan-1 HS
chains. Our results demonstrate that both syndecan-1 and
perlecan are degraded by HPSE-1 as purified HS entities and
confirm the role of syndecan-1 as an important modulator of
tumor cell invasion.
Invasion and metastasis are characteristic features of malig-
nant tumors and are among the greatest impediments to curing
cancer. Substantial evidence accumulated over the last 3 de-
cades indicates that HSPG acts to inhibit invasion by promot-
ing tight cell-cell and cell-ECM interactions (1, 3, 5). Degrada-
tion of HS chains weakens cell-cell and cell-matrix adhesion in
melanoma and other cells (28, 53–54). Furthermore, studies
documenting a diminished quantity and quality of HS isolated
from transformed cells have demonstrated a reduction in cel-
lular adhesive capacities (1, 3, 5). The results of our HS immu-
nostaining experiments confirm a role for HPSE-1 in the enzy-
matic degradation of HS. It is therefore conceivable that
HPSE-1 could play a role in restructuring HS and thus promote
metastatic spread.
HSPG can act both as reservoirs of growth factors (14, 31)
and as co-receptors for ligand binding and subsequent intra-
cellular signaling (1, 3). These heparin-binding factors are in-
volved in growth, invasion, angiogenesis, and tumor progres-
sion (1–3, 5). Free HS chains bind ligands and replace the
biological activities of cell-surface HSPG depending on their
size and sequence (1–5). HS degradative enzymes, such as
heparitinases, heparinases from F. heparinum, or endoglu-
cosaminidases, cleave HS to di- and tetrasaccharides (16–17,
27), which are too short for growth factor and ECM ligand
FIG. 5. WiDr perlecan HS does not inhibit HPSE-1-mediated
invasion of melanoma cells. Brain metastatic melanoma cells (70W)
were placed in invasion chambers (0.8 m diameter pores) in the
presence or absence of HPSE-1 (100 ng/ml), WiDr perlecan HS (8
ng/ml), or both, and incubated in DMEM/F-12 for 24 h at 37 °C. At that
time, the medium in upper invasive chambers was exchanged for fresh
DMEM/F-12, and invasion assays were continued for additional 24 h at
37 °C. Cells that invaded through the invasion chambers were stained
with Diff-Quick staining kit, photographed, and counted (see ‘‘Experi-
mental Procedures’’). Bars represent the mean  S.D. of triplicate
determinations (*, p  0.05). Student’s t test was used as a statistical
method.
TABLE III
HPSE-1, heparitinase, -elimination, or Pronase Syndecan-1 pretreatments, effects on HPSE-1-induced melanoma cell invasion
Syndecan-1 HPSE-1
Invasion (fold increase), enzymatic pretreatmenta
-Elimination Pronase Heparitinase HPSE-1
ng/ml
0 0 1.0  0.13 1.0  0.27 1.0  0.14 NDb
0 300 2.0  0.13c 2.1  0.07c 2.4  0.50c NDb
50 300 1.0  0.19 1.1  0.18 2.6  0.32c 0.7  0.10
a Syndecan-1 or mock buffer was pretreated with indicated enzymes for 16 h; enzymes were then inactivated, and digested syndecan-1 was added
to invasion assays (see ‘‘Experimental Procedures’’).
b ND, not determined.
c p  0.05 when compared with negative control (no HPSE-1 treatment). Student’s t test was used as statistical method.
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binding. On the other hand, HPSE-1 is an endo--D-glucuron-
idase that cleaves HS at specific intrachain sites resulting in
fragments of appreciable size (10–20 sugar units; see Refs.
13–15). Cleavage depends on the correct HS sequence (51, 55)
and possibly steric hindrance of the long HS chains that are
attached to the core protein. HPSE-1 also requires long incu-
bation periods, even at its pH optimum, to achieve substantial
degradation of HS (24, 35, 37, 46). HPSE-1 is therefore a highly
regulated enzyme that makes selective cuts at specific se-
quences. At least some HS fragments released by HPSE-1
cleavage of proteoglycans are able to bind ligands, although
HPSE-1 degradation may alter activation and binding of
growth factors to either the free HS chains or the HS fragments
remaining on the core protein. For example, bFGF requires
only a 6–8-mer of HS, whereas FGF-8b needs longer chains
(14-mer) to bind and maintain its biological function (56). Our
results show that HPSE-1 is capable of removing HS chains
from both matrix and cell-surface proteoglycans. Our data also
suggest that the longer HS fragments produced by HPSE-1
maintain biological activity, unlike the short fragments pro-
duced by heparitinase. This confirms the notion that HPSE-1,
which degrades HS into significant size fragments, may aid
modulation of growth factor activities in metastasis.
Syndecan-1 is a cell-surface HSPG present at the cell-cell
contact sites, which functions in cellular adhesive, invasive,
and metastatic processes (1, 5). It is a significant component of
HSPG on brain metastatic melanoma cells and may act in
multiple ways to promote tumor progression in these cells.
Cell-surface syndecan-1 binds ECM components (including col-
lagen and fibronectin) and various growth factors (such as
bFGF, VEGF (57), keratinocyte growth factor, and others) via
its HS chains. The HS chains of syndecan also function as a
storage site for cytokines (1, 5) and act to promote binding of
growth factors to receptors (58).
HPSE-1 degradation of syndecan-1 HS modifies cellular re-
sponses by releasing associated growth factors (59) and dis-
rupting interactions with ECM and other cells (15). Addition-
ally, HPSE-1 degradation of syndecan-1 HS can interfere in
co-receptor function either by blocking formation of the tertiary
complexes (HSPG-kinase receptor-ligand) or by releasing free
HS chains that can then promote ligand binding and signaling.
In our system, syndecan-1 inhibits HPSE-1-induced invasion,
suggesting one mechanism by which syndecan-1 down-regula-
tion induces tumor progression. Furthermore, our experiments
suggest that HS chains are crucial for this biological activity
because either free HS chains obtained by -elimination of
syndecan-1 or HS chains resulting from HPSE-1 degradation of
syndecan-1 inhibited HPSE-1-induced invasion. According to
our activity assays, syndecan-1 is not acting to inhibit HPSE-1
enzymatic degradation either at the optimal pH of the enzymes
FIG. 6. Syndecan-1 does not inhibit
HPSE-1 enzymatic degradation of
FITC-HS at pH 4.5. A, FITC-HS was
incubated alone (E), or in the presence of
HPSE-1 (), HPSE-1 and syndecan-1 (f),
or syndecan-1 () in sodium acetate (50
mM, pH 4.5) for 24 h at 37 °C. Reaction
products were then separated by HPLC
(see ‘‘Experimental Procedures’’). B, per-
centage of digested FITC-HS derived from
HPLCs alone (column 1) or when HPSE-1
(column 2), HPSE-1 and syndecan-1 (col-
umn 3), or syndecan-1 (column 4), respec-
tively, were added. C, HPSE-1 at indi-
cated concentrations was incubated with
FITC-HS, and the percentage of degraded
FITC-HS was calculated as the area of the
curve that shifted to the right of non-
treated control curve. The open symbol is
the concentration of HPSE-1 used in A
and B. Standard deviations (2–5% of
values) were calculated but not shown for
clarity purposes.
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nor at pH 6.8 which is seen in cultured 70W melanoma cells
and in cancer. This suggests that syndecan-1 is acting through
other mechanisms that could include the following: 1) the pro-
duction of HS fragments that activate bFGF mitogenicity thus
bypassing the need for cell-surface syndecan-1 (60); 2) dimin-
ishing tight adhesion to the underlying ECM; and/or 3) increas-
ing melanoma cell motility.
There is mounting evidence for the involvement of perlecan
in tumor progression and vascularization (2, 3). The emerging
view from several investigations is that an aggressive behavior
in tumor cells coincides with an augmented synthesis and
secretion of this potent and ubiquitous molecule (3). Moreover,
the source of perlecan is dual because both cancer and stromal
cells synthesize it. Thus, growth of neoplastic cells may be
promoted by a relatively high and constant supply of this large
macromolecule that consists of HS and a core protein having
cell-adhesive motifs. In addition, perlecan HS binds growth
factors, i.e. FGF-7 for epithelial cells and bFGF for mesenchy-
mal cells (2, 3, 32). As with syndecan-1, digestion of perlecan
HS by HPSE-1 can release active growth factors to bind to cells,
stimulating angiogenesis, growth, migration, and invasion. In
our hands, perlecan HS fragments did not inhibit invasion in
the same manner as syndecan-1 HS fragments when tested
both directly and indirectly. Purified perlecan HS fragments
from WiDr cells did not inhibit melanoma cell invasion. Perle-
can is the primary HSPG in MatrigelTM, thus present and
degraded when HPSE-1 was added in the invasion assays.
Accordingly, we were able to detect enhanced invasive effects
with HPSE-1 and the subsequent decrease in invasion due to
syndecan-1 in the presence of HPSE-1-generated HS degrada-
tive products from MatrigelTM. During tumor cell invasion,
perlecan may bind a wider range of growth factors than the
limited set in MatrigelTM and thus may be able to promote
invasion in vivo. This indicates that distinct substrates are able
to differentially modify the invasive behavior of tumor cells.
Although the full extent of HPSE-1 action in regulating brain
metastatic melanoma (or tumor metastasis in general) is not
completely understood, this enzyme likely participates in sev-
eral key events. First, prior to gaining entrance into the vas-
culature, brain metastatic melanoma cells must degrade inter-
stitial stroma and ECM that is rich in perlecan. Second,
HPSE-1 produced by neoplastic and surrounding inflammatory
cells is thought to be an important participant in angiogenesis
because it can release heparin-binding growth factors (such as
FGFs and/or VEGF). Third, HPSE-1 produced by endothelial
cells can also aid in remodeling the ECM surrounding the
developing vessel (61). Considering our results, it is also plau-
sible to propose a pH-dependent action by HPSE-1 in invasive
mechanisms. At neutral pH, HPSE-1 may be primarily inac-
tive. However, under conditions where pH becomes acidic (as in
invasion and inflammatory processes), HPSE-1 can become
activated and degrade HS of HSPG, i.e. syndecan-1 and
perlecan.
Besides perlecan and syndecan-1, other proteoglycans
should be considered as potential substrates of HPSE-1 degra-
dation because different HSPG may contain the same HS se-
quences (62). HPSE-1 can act on multiple HSPG both at the cell
surface and in the ECM in a cell type-specific fashion, which
may then influence tumor progression. For example, synde-
can-4 is essential for cell adhesion and signaling through in-
teraction with integrins (63). Therefore, degradation of synde-
can-4 HS can affect cell behavior important for tumor
progression. Furthermore, once released by HPSE-1, HS can
have similar biological activities despite their origin from dif-
ferent HSPG (64).
In conclusion, perlecan and syndecan-1 HS degradation not
only confers an invasive advantage, but it may be an essential
component of the multifactorial and highly complex processes
that lead to tumor growth and metastasis. The metastatic
phenotype is considered decisive for tumor progression, and
several key molecules involved in these complex biological
events are potential candidates for therapeutic intervention.
HPSE-1 should be considered one of these. Therapies focusing
FIG. 7. Syndecan-1 does not inhibit HPSE-1 activity using bi-
otinylated HS as a substrate. A, HPSE-1 and syndecan-1 were incu-
bated with biotinylated HS (b-HS) at indicated concentrations, and
then undigested b-HS was bound to bFGF ELISA plates (Takara.Mi-
rus.Bio, Madison, WI). Biotinylated HS, digested by HPSE-1, remained
unbound and discarded during PBS washes. Bound b-HS was detected
with HRP-avidin followed by a colorimetric assay as per the manufac-
turer’s instructions (see ‘‘Experimental Procedures’’). HPSE-1 activity
was determined by comparison with known HPSE-1 concentrations. B,
HPSE-1 concentration curve (0.125–4 ng/ml) used to calculate HPSE-1
activity. Absorbance at 450 nm was plotted against HPSE-1 concentra-
tion and fit (4 parameter equation) with Kaleidagraph (Synergy Soft-
ware, Reading, PA) according to manufacturer’s instructions.
FIG. 8. Syndecan-1 does not inhibit HPSE-1 enzymatic degra-
dation of FITC-HS at pH 6.8. A, FITC-HS was incubated alone
(column 1), or in presence of HPSE-1 (column 2), HPSE-1 and synde-
can-1 (column 3), or syndecan-1 (column 4), in reaction buffer (pH 6.8,
Takara.Mirus.Bio) for 18 h at 37 °C. Reaction products were then sep-
arated by HPLC (see ‘‘Experimental Procedures’’). Results are reported
as percentage of digested FITC-HS. B, HPSE-1 was incubated at indi-
cated concentrations with FITC-HS. Percentage of degraded FITC-HS
was calculated as area of the curve that shifted to the right compared
with non-HPSE-1-treated samples (control curve). The open symbol
represents HPSE-1 concentration used in A. Standard deviations
(2–5% of values) were calculated but not shown for clarity purposes.
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on abrogating HPSE-1 expression and action through the use of
specific inhibitors may prove to be beneficial and potentially
improve cancer treatment.
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